Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 25, 2023
Lead Product(s) : KM10544
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Emmaus Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Emmaus intends to advance the licensed technology to complete in-vivo studies to determine disease selection for KM10544 which, if successful, would be followed by Investigational New Drug enabling studies.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2021
Lead Product(s) : KM10544
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Emmaus Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 18, 2017
Lead Product(s) : KM-023
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 05, 2011
Lead Product(s) : KM-023
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
